DHR
DANAHER CORP /DE/
NYSE · Healthcare · Medical - Diagnostics & Research · US
$234.41
+1.87%Year over year
Reported trailing growth
- Revenue
- +5.5%
- EBITDA
- +3.2%
- EBIT
- -2.8%
- EPS
- +25.4%
- Free cash flow
- +14.2%
- Operating cash flow
- +8.6%
Forward estimates
Based on analyst estimates
- Revenue
- +8.9%
- EBITDA
- +37.2%
- EPS
- +48.6%
Three-year CAGR
- Revenue
- -2.7%
- EBITDA
- -9.9%
- EBIT
- -12.0%
- Net income
- -20.6%
- EPS
- -19.7%
- Free cash flow
- -10.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026